• Explore /
  • Poster
  • / Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.

Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.

Abstract Poster

Authors

null

Roy S. Herbst

Yale University School of Medicine, Yale Cancer Center, New Haven, CT

Roy S. Herbst , Paul Baas , Jose Luis Perez-Gracia , Enriqueta Felip , Dong-Wan Kim , Ji-Youn Han , Julian R. Molina , Joo-Hang Kim , Catherine Dubos Arvis , Myung-Ju Ahn , Margarita Majem , Mary J. Fidler , Veerle Surmont , Marcelo Garrido , Yue Shentu , Marisa Dolled-Filhart , Ellie Im , Edward B. Garon , Gilberto Castro Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Clinical Trial Registration Number

NCT01905657

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3030)

DOI

10.1200/JCO.2016.34.15_suppl.3030

Abstract #

3030

Poster Bd #

352

Abstract Disclosures

Similar Posters

First Author: Paul Baas

First Author: Nikhil Shukla

First Author: Roy S. Herbst

First Author: Biagio Ricciuti